

*Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representations to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BBI LIFE SCIENCES CORPORATION**

**BBI 生命科學有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1035)**

### **GRANT OF SHARE OPTIONS**

The Board announces that on 29 April 2019, the Company granted 4,720,000 Options at an exercise price of HK\$ 2.48 per Share, subject to acceptance of the grantees, under the Share Option Scheme. None of the grantees of the Options is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them.

This announcement is made by the board (the “**Board**”) of directors (“**Directors**”) of BBI Life Sciences Corporation (the “**Company**”) pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange.

The Board announces that on 29 April 2019 (the “Date of Grant”), the Company granted 4,720,000 share options (the “Option(s)”) to subscribe for an aggregate of 4,720,000 ordinary shares of HK\$ 0.01 per share (the “Share(s)”) to 83 eligible persons, subject to acceptance of the grantees, under the Company’s post-IPO share option scheme adopted on 8 December 2014 (the “Share Option Scheme”). The details of the Options granted are set out below:

Date of Grant: 29 April 2019

Exercise price of Options granted: Each Option shall entitle the holder of the Option to subscribe for Shares upon exercise of such Option at an exercise price of HK\$ 2.48 per Share, being the highest of (i) the closing price of the Shares on the Date of Grant, (ii) the

average closing price of the Shares as quoted on the Stock Exchange for the five business days immediately preceding the Date of Grant

Number of Options granted: 4,720,000 Options

Closing price of the Shares on the Date of Grant: HK\$ 2.44 per Share

Average closing price of the Shares as quoted on the Stock Exchange for the five business days immediately preceding the Date of Grant: HK\$2.48 per Share

Validity period of the Options: 29 April 2019 to 28 April 2029, both dates inclusive

None of the grantees of the Options is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them.

By order of the Board  
**BBI Life Sciences Corporation**  
**Wang Qisong**  
*Chairman*

Hong Kong, 29 April 2019

As at the date of this announcement, the executive Directors are Mr. WANG Qisong, Ms. WANG Luojia, and Ms. WANG Jin; the non-executive Director is Mr. ZHOU Mi; and the independent non-executive Directors are Mr. XIA Lijun, Mr. HO Kenneth Kai Chung, and Mr. LIU Jianjun.